Takeda To Buy U.S. Vaccine Maker Inviragen For Up To $250 Million
This article was originally published in PharmAsia News
Executive Summary
Takeda Pharmaceutical said it plans to pay as much as $250 million for Inviragen, a U.S. vaccine maker with a Singapore subsidiary, in part to gain a preventative for dengue infection.